1. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood
- Author
-
Dianna L. Ng, Gregory M. Goldgof, Brian R. Shy, Andrew G. Levine, Joanna Balcerek, Sagar P. Bapat, John Prostko, Mary Rodgers, Kelly Coller, Sandra Pearce, Sergej Franz, Li Du, Mars Stone, Satish K. Pillai, Alicia Sotomayor-Gonzalez, Venice Servellita, Claudia Sanchez San Martin, Andrea Granados, Dustin R. Glasner, Lucy M. Han, Kent Truong, Naomi Akagi, David N. Nguyen, Neil M. Neumann, Daniel Qazi, Elaine Hsu, Wei Gu, Yale A. Santos, Brian Custer, Valerie Green, Phillip Williamson, Nancy K. Hills, Chuanyi M. Lu, Jeffrey D. Whitman, Susan L. Stramer, Candace Wang, Kevin Reyes, Jill M. C. Hakim, Kirk Sujishi, Fariba Alazzeh, Lori Pham, Edward Thornborrow, Ching-Ying Oon, Steve Miller, Theodore Kurtz, Graham Simmons, John Hackett, Michael P. Busch, and Charles Y. Chiu
- Subjects
Science - Abstract
Highly accurate antibody tests for SARS-CoV-2 are needed for surveillance in low-prevalence populations. Here, the authors find seroprevalence of less than 1% in two San Francisco Bay Area populations at the beginning of April, and that seroreactivity is generally predictive of in vitro neutralising activity.
- Published
- 2020
- Full Text
- View/download PDF